Increased activated human T cell lymphotropic virus type I (HTLV-I) Tax11-19-specific memory and effector CD8+ cells in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis: Correlation with HTLV-I provirus load

Journal of Infectious Diseases

Volumn 183, Issue 2, 2001, Pages 197-205

  Nagai, Masahiro ^a   Kubota, Ryuji ^a   Greten, Tim F ^b   Schneck, Jonathan P ^b   Leist, Thomas P ^a   Jacobson, Steven ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD27 ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN; HLA DR ANTIGEN;

ADULT; ARTICLE; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; EFFECTOR CELL; FEMALE; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; LYMPHOCYTE; MALE; MEMORY CELL; PARAPLEGIA; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPINAL CORD DISEASE; T LYMPHOCYTE; VIRUS LOAD;

ADULT; ANTIGENS, CD27; ANTIGENS, CD45; CD8-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY TESTS, IMMUNOLOGIC; DNA, VIRAL; FEMALE; FLOW CYTOMETRY; GENE PRODUCTS, TAX; HLA-A2 ANTIGEN; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC MEMORY; LYMPHOCYTE ACTIVATION; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PARAPARESIS, TROPICAL SPASTIC; PEPTIDES; PORE FORMING CYTOTOXIC PROTEINS; PROVIRUSES; T-LYMPHOCYTES, REGULATORY; VIRAL LOAD;

EID: 0035863547     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/317932     Document Type: Article

References (39)

1. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis
2. Osame M, Usuku K, Izumo S, et al. HTLV-I–associated myelopathy: a new clinical entity. Lancet 1986;1:1031–2
3. Kaplan JE, Osame M, Kubota H, et al. The risk of development of HTLVI–associated myelopathy/tropical spastic paraparesis among persons infected with HTLV-I. J Acquir Immune Defic Syndr 1990;3:1096–101
4. Yoshida M, Osame M, Kawai H, et al. Increased replication of HTLV-I in HTLV-I–associated myelopathy. Ann Neurol 1989;26:331–5
5. Kira J, Koyanagi Y, Yamada T, et al. Increased HTLV-I proviral DNA in HTLV-I–associated myelopathy: a quantitative polymerase chain reaction study. Ann Neurol 1991;29:194–201.
6. Nagai M, Usuku K, Matsumoto W, et al. Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP. J Neurovirol 1998;4: 586–93
7. Jacobson S, Shida H, McFarlin DE, Fauci AS, Koenig S. Circulating CD81 cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLVI–associated neurological disease. Nature 1990;348:245–8.
8. Jacobson S, McFarlin DE, Robinson S, et al. HTLV-I–specific cytotoxic T lymphocytes in the cerebrospinal fluid of patients with HTLV-I–associated neurological disease. Ann Neurol 1992;32:651–7.
9. Parker CE, Daenke S, Nightingale S, Bangham CR. Activated, HTLV-1–specific cytotoxic T-lymphocytes are found in healthy seropositives as well as in patients with tropical spastic paraparesis. Virology 1992;188:628–36.
10. Koenig S, Woods RM, Brewah YA, et al. Characterization of MHC class I restricted cytotoxic T cell responses to tax in HTLV-1–infected patients with neurologic disease. J Immunol 1993;151:3874–83.
11. Parker CE, Nightingale S, Taylor GP, Weber J, Bangham CR. Circulating anti-Tax cytotoxic T lymphocytes from human T-cell leukemia virus type I–infected people, with and without tropical spastic paraparesis, recognize multiple epitopes simultaneously. J Virol 1994;68:2860–8.
12. Elovaara I, Koenig S, Brewah AY, Woods RM, Lehky T, Jacobson S. High human T cell lymphotropic virus type 1 (HTLV-1)–specific precursor cytotoxic T lymphocyte frequencies in patients with HTLV-1–associatedneurological disease. J Exp Med 1993;177:1567–73.
13. Kubota R, Kawanishi T, Matsubara H, Manns A, Jacobson S. Demonstration of human T lymphotropic virus type I (HTLV-I) tax–specific CD81 lymphocytes directly in peripheral blood of HTLV-I–associated myelopathy/tropical spastic paraparesis patients by intracellular cytokine detection. J Immunol 1998;161:482–8
14. Izumo S, Ijichi T, Higuchi I, Tashiro A, Takahashi K, Osame M. Neuropathology of HTLV-I–associated myelopathy: a report of two autopsy cases. Acta Paediatr Jpn 1992;34:358–64.
15. Umehara F, Izumo S, Nakagawa M, et al. Immunocytochemical analysis of the cellular infiltrate in the spinal cord lesions in HTLV-I–associated myelopathy. J Neuropathol Exp Neurol 1993;52:424–30.
16. Immunologic analysis of a spinal cord-biopsy specimen from a patient with human T-cell lymphotropic virus type I-associated neurologic disease
17. Umehara F, Nakamura A, Izumo S, et al. Apoptosis of T lymphocytes in the spinal cord lesions in HTLV-I–associated myelopathy: a possible mechanism to control viral infection in the central nervous system. J Neuropathol Exp Neurol 1994;53:617–24.
18. Howard MC, Spack EG, Choudhury K, Greten TF, Schneck JP. MHC-based diagnostics and therapeutics: clinical applications for disease-linked genes. Immunol Today 1999;20:161–5.
19. Greten TF, Slansky JE, Kubota R, et al. Direct visualization of antigenspecific T cells: HTLV-1 Tax11-19–specific CD8(1) T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patients. Proc Natl Acad Sci USA 1998;95:7568–73.
20. Gray CM, Lawrence J, Schapiro JM, et al. Frequency of class I HLA-restricted anti-HIV CD81 T cells in individuals receiving highly active antiretroviral therapy (HAART). J Immunol 1999;162:1780–8
21. Gray CM, Lawrence J, Schapiro JM, et al. Frequency of class I HLA-restricted anti-HIV CD81 T cells in individuals receiving highly active antiretroviral therapy (HAART). J Immunol 1999;162:1780–8. 21. Hamann D, Baars PA, Rep MH, et al. Phenotypic and functional separation of memory and effector human CD81 T cells. J Exp Med 1997;186:1407–18.
22. Blattner WA, ed. Human retrovirology: HTLV. New York: Raven Press
23. Blomberg K, Hautala R, Lovgren J, Mukkala VM, Lindqvist C, Akerman K. Time-resolved fluorometric assay for natural killer activity using target cells labelled with a fluorescence enhancing ligand. J Immunol Methods 1996;193:199–206.
24. Kubota R, Soldan SS, Martin R, Jacobson S. An altered peptide ligand antagonizes antigen-specific T cells of patients with human T lymphotropic virus type I–associated neurological disease. J Immunol 2000;164:5192–8.
25. Tateno M, Kondo N, Itoh T, Chubachi T, Togashi T, Yoshiki T. Rat lymphoid cell lines with human T cell leukemia virus production. I. Biological and serological characterization. J Exp Med 1984;159:1105–16.
26. Griffiths GM, Mueller C. Expression of perforin and granzymes in vivo: potential diagnostic markers for activated cytotoxic cells. Immunol Today 1991;12:415–9.
27. Hamann D, Roos MT, van Lier RA. Faces and phases of human CD8 Tcell development. Immunol Today 1999;20:177–80.
28. Jacobson S, Zaninovic V, Mora C, et al. Immunological findings in neurological diseases associated with antibodies to HTLV-I: activated lymphocytes in tropical spastic paraparesis. Ann Neurol 1988;23(Suppl):S196–200.
29. Usuku K, Sonoda S, Osame M, et al. HLA haplotype-linked high immune responsiveness against HTLV-I in HTLV-I-associated myelopathy: comparison with adult T cell leukemia/lymphoma. Ann Neurol 1988;23(Suppl): S143–50.
30. Itoyama Y, Minato S, Kira J, et al. Spontaneous proliferation of peripheral blood lymphocytes increased in patients with HTLV-I–associated myelopathy. Neurology 1988;38:1302–7.
31. Kuroda Y, Matsui M, Takashima H, Kurohara K. Granulocyte-macrophage colony-stimulating factor and interleukin-1 increase in cerebrospinal fluid, but not in serum, of HTLV-I–associated myelopathy. J Neuroimmunol 1993;45:133–6.
32. Kuroda Y, Matsui M. Cerebrospinal fluid interferon-g is increased in HTLVI–associated myelopathy. J Neuroimmunol 1993;42:223–6
33. Nakamura S, Nagano I, Yoshioka M, Shimazaki S, Onodera J, Kogure K. Detection of tumor necrosis factor–a–positive cells in cerebrospinal fluid of patients with HTLV-I–associated myelopathy. J Neuroimmunol 1993; 42:127–30.
34. Bell EB, Sparshott SM, Bunce C. CD41 T cell memory, CD45R subsets and the persistence of antigen: a unifying concept. Immunol Today 1998;19: 60–4.
35. Callan MF, Tan L, Annels N, et al. Direct visualization of antigen-specific CD81 T cells during the primary immune response to Epstein-Barr virus in vivo. J Exp Med 1998;187:1395–1402.
36. Etoh K, Yamaguchi K, Tokudome S, et al. Rapid quantification of HTLVI provirus load: detection of monoclonal proliferation of HTLV-I–infected cells among blood donors. Int J Cancer 1999;81:859–64.
37. Kubota R, Kawanishi T, Matsubara H, Manns A, Jacobson S. HTLV-I–specific IFN-g1 CD81 lymphocytes correlate with the proviral load in peripheral blood of infected individuals. J Neuroimmunol 2000;102:208–15.
38. Taylor GP, Hall SE, Navarrete S, et al. Effect of lamivudine on human Tcell leukemia virus type 1 (HTLV-1) DNA copy number, T-cell phenotype, and anti-Tax cytotoxic T-cell frequency in patients with HTLV-1–associated myelopathy. J Virol 1999;73:10289–95.
39. Wodarz D, Nowak MA, Bangham CR. The dynamics of HTLV-I and the CTL response. Immunol Today 1999;20:220–27.